PP79 Efficiency Frontier Analysis Of Fostemsavir For Patients Living With Multidrug-Resistant HIV-1
Lívia Nassif, Álex Martins, Bárbara Santos, Isabela Rossi, Ludmila Gargano, Francisco Acurcio, Juliana Alvares-Teodoro, Augusto Guerra · 2025
Read PP79 Efficiency Frontier Analysis Of Fostemsavir For Patients Living With Multidrug-Resistant HIV-1 by Lívia Nassif, Álex Martins, Bárbara Santos, Isabela Rossi, Ludmila Gargano, Francisco Acurcio, Juliana Alvares-Teodoro, Augusto Guerra (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768744.txt.
Description
Livia Nassif and co-authors present a 2025 study of the value of a newer HIV drug for patients whose virus resists many standard drugs. HIV weakens the immune system, and resistance to standard therapy is common, which creates a need for fresh options. The drug is added to an optimized background regimen.
From the view of Brazil's public health system, the team weighed added costs against added health gains over one year. The comparison was the background regimen alone. An efficiency frontier method sorted the options by value. The analysis helps decision makers judge whether the drug earns its price for this hard-to-treat group.
Catalog record
| CREATOR | Lívia Nassif, Álex Martins, Bárbara Santos, Isabela Rossi, Ludmila Gargano, Francisco Acurcio, Juliana Alvares-Teodoro, Augusto Guerra |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |